Transthyretin Amyloidosis Treatment Market (By Type: ATTR-PN, ATTR-CM; By Therapy; By Disease Type; By Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Transthyretin Amyloidosis Treatment Market 

5.1. COVID-19 Landscape: Transthyretin Amyloidosis Treatment Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Transthyretin Amyloidosis Treatment Market, By Type

8.1. Transthyretin Amyloidosis Treatment Market, by Type, 2022-2030

8.1.1. ATTR-PN

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. ATTR-CM

8.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Transthyretin Amyloidosis Treatment Market, By Therapy

9.1. Transthyretin Amyloidosis Treatment Market, by Therapy, 2022-2030

9.1.1. Targeted Therapy

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Supportive Therapy

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. Pipeline Therapy

9.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Transthyretin Amyloidosis Treatment Market, By Disease Type 

10.1. Transthyretin Amyloidosis Treatment Market, by Disease Type, 2022-2030

10.1.1. Hereditary Transthyretin Amyloidosis

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Wild Type Amyloidosis

10.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Transthyretin Amyloidosis Treatment Market, By Distribution Channel 

11.1. Transthyretin Amyloidosis Treatment Market, by Distribution Channel, 2022-2030

11.1.1. Hospital Pharmacies

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. Specialty Pharmacies

11.1.2.1. Market Revenue and Forecast (2017-2030)

11.1.3. Retail Pharmacies

11.1.3.1. Market Revenue and Forecast (2017-2030)

11.1.4. Online Pharmacies

11.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Transthyretin Amyloidosis Treatment Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Type (2017-2030)

12.1.2. Market Revenue and Forecast, by Therapy (2017-2030)

12.1.3. Market Revenue and Forecast, by Disease Type (2017-2030)

12.1.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Type (2017-2030)

12.1.5.2. Market Revenue and Forecast, by Therapy (2017-2030)

12.1.5.3. Market Revenue and Forecast, by Disease Type (2017-2030)

12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Type (2017-2030)

12.1.6.2. Market Revenue and Forecast, by Therapy (2017-2030)

12.1.6.3. Market Revenue and Forecast, by Disease Type (2017-2030)

12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Type (2017-2030)

12.2.2. Market Revenue and Forecast, by Therapy (2017-2030)

12.2.3. Market Revenue and Forecast, by Disease Type (2017-2030)

12.2.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Type (2017-2030)

12.2.5.2. Market Revenue and Forecast, by Therapy (2017-2030)

12.2.5.3. Market Revenue and Forecast, by Disease Type (2017-2030)

12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Type (2017-2030)

12.2.6.2. Market Revenue and Forecast, by Therapy (2017-2030)

12.2.6.3. Market Revenue and Forecast, by Disease Type (2017-2030)

12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Type (2017-2030)

12.2.7.2. Market Revenue and Forecast, by Therapy (2017-2030)

12.2.7.3. Market Revenue and Forecast, by Disease Type (2017-2030)

12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Type (2017-2030)

12.2.8.2. Market Revenue and Forecast, by Therapy (2017-2030)

12.2.8.3. Market Revenue and Forecast, by Disease Type (2017-2030)

12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Type (2017-2030)

12.3.2. Market Revenue and Forecast, by Therapy (2017-2030)

12.3.3. Market Revenue and Forecast, by Disease Type (2017-2030)

12.3.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Type (2017-2030)

12.3.5.2. Market Revenue and Forecast, by Therapy (2017-2030)

12.3.5.3. Market Revenue and Forecast, by Disease Type (2017-2030)

12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Type (2017-2030)

12.3.6.2. Market Revenue and Forecast, by Therapy (2017-2030)

12.3.6.3. Market Revenue and Forecast, by Disease Type (2017-2030)

12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Type (2017-2030)

12.3.7.2. Market Revenue and Forecast, by Therapy (2017-2030)

12.3.7.3. Market Revenue and Forecast, by Disease Type (2017-2030)

12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Type (2017-2030)

12.3.8.2. Market Revenue and Forecast, by Therapy (2017-2030)

12.3.8.3. Market Revenue and Forecast, by Disease Type (2017-2030)

12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Type (2017-2030)

12.4.2. Market Revenue and Forecast, by Therapy (2017-2030)

12.4.3. Market Revenue and Forecast, by Disease Type (2017-2030)

12.4.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Type (2017-2030)

12.4.5.2. Market Revenue and Forecast, by Therapy (2017-2030)

12.4.5.3. Market Revenue and Forecast, by Disease Type (2017-2030)

12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Type (2017-2030)

12.4.6.2. Market Revenue and Forecast, by Therapy (2017-2030)

12.4.6.3. Market Revenue and Forecast, by Disease Type (2017-2030)

12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Type (2017-2030)

12.4.7.2. Market Revenue and Forecast, by Therapy (2017-2030)

12.4.7.3. Market Revenue and Forecast, by Disease Type (2017-2030)

12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Type (2017-2030)

12.4.8.2. Market Revenue and Forecast, by Therapy (2017-2030)

12.4.8.3. Market Revenue and Forecast, by Disease Type (2017-2030)

12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Type (2017-2030)

12.5.2. Market Revenue and Forecast, by Therapy (2017-2030)

12.5.3. Market Revenue and Forecast, by Disease Type (2017-2030)

12.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Type (2017-2030)

12.5.5.2. Market Revenue and Forecast, by Therapy (2017-2030)

12.5.5.3. Market Revenue and Forecast, by Disease Type (2017-2030)

12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Type (2017-2030)

12.5.6.2. Market Revenue and Forecast, by Therapy (2017-2030)

12.5.6.3. Market Revenue and Forecast, by Disease Type (2017-2030)

12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

Chapter 13. Company Profiles

13.1. Pfizer Inc.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Johnson & Johnson Services, Inc.

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Ionis Pharmaceuticals, Inc.

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Alnylam Pharmaceuticals, Inc.

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. BridgeBio Pharma, Inc.

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Bristol-Myers Squibb Company

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Acrotech Biopharma

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. AstraZeneca

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Astellas Pharma, Inc.

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Prothena

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Report Detail

Proceed To Buy

USD 3500
USD 7000